CB1 Antibody Segmentation for Peripheral Metabolic Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Small molecule CB1 receptor antagonists have adverse central nervous system effects and poor safety profiles, while peripherally-restricted therapies may not fully exploit metabolic benefits due to limited receptor targeting.
Innovation Solution
Development of CB1 receptor antigen-binding proteins, such as antibodies, that specifically bind to the CB1 receptor, particularly targeting the extracellular loop 2 domain, to antagonize G-protein signaling without penetrating the central nervous system, offering reduced clearance and less frequent administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CB1 receptor antagonists are used, then metabolic benefits are achieved, but adverse CNS effects and poor safety profiles occur
Solution Approach 1:
The invention segments the CB1 receptor population into central and peripheral compartments by using a large molecule antibody that cannot penetrate the blood-brain barrier. This spatial segmentation allows selective antagonism of peripheral CB1 receptors while leaving central receptors unaffected, thereby achieving metabolic benefits without adverse CNS effects
Solution Approach 2:
The patent introduces an antibody as an intermediary molecule that binds to CB1 receptors in peripheral tissues. This antibody acts as a mediator that blocks CB1 signaling in metabolically relevant tissues (adipose, liver, muscle, GI tract) without requiring CNS penetration, thus achieving therapeutic effect while avoiding CNS side effects
2Object-affected harmful factors
If peripherally-restricted small molecule therapies are used, then CNS side effects are reduced, but receptor targeting and metabolic benefits are limited
Solution Approach 1:
The invention changes the molecular size parameter from small molecule to large molecule (antibody), which fundamentally alters tissue distribution properties. This parameter change enables peripherally-restricted activity while increasing affinity and specificity for CB1 receptors, thereby improving metabolic benefits without CNS penetration
3Strength
If CB1 receptor antagonists with high CNS penetration are used, then central effects are achieved, but adverse CNS effects occur
Solution Approach 1:
The invention adds a spatial dimension constraint by using a large molecule antibody that is physically excluded from the CNS compartment. This dimensional approach (molecular size-based compartmentalization) allows high affinity binding in peripheral tissues while automatically preventing CNS entry, thereby achieving selective peripheral antagonism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CB1 antagonistic antibodies effectively reduce body weight and improve metabolic parameters like plasma glucose and insulin levels with reduced CNS penetration, providing a safer therapeutic option compared to small molecule antagonists.
Implementation Method 1
The CB1 receptor antibodies may comprise antibodies that antagonize signaling of the cannabinoid receptor CB1
Data Source
AI summary
This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.